NMN 1000mg | Double Strength | β-NMN for NAD+, Sirtuins & Cellular Longevity

1000 mg of β-NMN per capsule, 99%+ HPLC-tested. The double-strength NAD+ precursor for adults over 50, anyone running a metabolically demanding training or recovery cycle, post-menopausal physiologies navigating the steeper NAD+ decline, and the people who tried 500 mg for two months and felt nothing — the published trial range (Yoshino 2021 Science, Yamaguchi 2022, Liao 2021, Igarashi 2022) places NMN's measurable effects in the 250–900 mg/day window, and the high end of that window is where the slower-responding, older, more depleted physiologies usually land.

The 30-second answer

• 1000 mg β-NMN, single capsule, daily. The double-strength version of our NMN line — choose this if you're 50+, stacking against a high cortisol or training load, navigating menopause or andropause, recovering from illness or surgery, or didn't notice an effect at 500 mg after 6–8 weeks of consistent daily use.
• NAD+ falls roughly 50% between age 40 and 60 (Massudi 2012 PLoS ONE, McReynolds 2020 Cell Metabolism) and the dose required to push tissue NAD+ back toward youthful range scales with how depleted you started. The Yoshino 2021 prediabetic-women trial used 250 mg and saw insulin-sensitivity gains; Yamaguchi 2022 ran 250 mg in older adults and saw walking-speed and grip-strength gains; Liao 2021 dose-finding tested up to 600 mg and saw a clear walking-speed plateau past that point in older adults; practitioner protocols routinely run 500–1000 mg for the population already noticing the decline.
• Best taken: morning, with breakfast, daily, not cycled. Pair with a methyl donor (TMG / trimethylglycine) if you're stacking heavily — see Stacking below.
• One capsule = 30-day supply. No proprietary blend, no fillers, vegan HPMC capsule, third-party COA available on request.

Why NMN sits at the center of the longevity stack

NAD+ (nicotinamide adenine dinucleotide) is the coenzyme your cells use to do four jobs that all decline with age:

• Run the electron transport chain — NAD+/NADH is the redox shuttle that lets Complex I of the mitochondrial inner membrane accept electrons from the Krebs cycle and pass them down the chain to drive ATP synthesis. No NAD+, no electron flow, no ATP. Mitochondrial dysfunction is one of the canonical hallmarks of aging in the López-Otín 2013 framework and remains so in the 2023 update.
• Activate sirtuins — SIRT1, SIRT3, and SIRT6 are NAD+-dependent deacetylases that regulate the cellular stress response, mitochondrial biogenesis, DNA repair, telomere maintenance, and inflammation control. They literally consume NAD+ to do their job — every deacetylation reaction cleaves NAD+ — and their activity drops as NAD+ falls. Sirtuin underactivity is downstream of NAD+ depletion, not a parallel problem.
• Power DNA repair — PARP enzymes (poly-ADP-ribose polymerases) consume NAD+ to repair single-strand DNA breaks. The more genomic damage accumulates with age, sun exposure, oxidative stress, or chronic inflammation, the more PARP activity climbs and the more NAD+ gets pulled out of the available pool. This is one of the mechanisms by which chronic inflammation and lifestyle stress accelerate the NAD+ decline.
• Regulate the circadian clock — NAMPT (nicotinamide phosphoribosyltransferase, the rate-limiting enzyme in the salvage pathway that recycles nicotinamide back to NMN) is itself clock-regulated, and SIRT1 deacetylates BMAL1 in the core clock loop. NAD+ has a measurable daily rhythm driven by this feedback. Disrupted sleep, shift work, and chronic late-night light exposure flatten that rhythm and drop average tissue NAD+.

NMN (β-nicotinamide mononucleotide) is a single enzymatic step (catalyzed by NMNAT1/2/3 in different cellular compartments) away from NAD+. Of the three commonly available oral NAD+ precursors — NR (nicotinamide riboside), NMN, and niacinamide — NMN is the most direct precursor and the most heavily studied in the human longevity-focused trial literature between 2020 and 2024. Niacinamide raises NAD+ but inhibits sirtuins at high doses (it's a feedback inhibitor); NR has a longer published safety database and a different absorption pathway (the SLC12A8 transporter for NMN was characterized in 2019 by Grozio et al. Nature Metabolism); the practical case for NMN is conversion efficiency and the depth of recent trial work in the older-adult population.

Why double strength — the case for 1000 mg over 500 mg

The 500 mg dose (see Pure NMN 500 mg) is the right starting point for under-50 longevity-baseline use. The practical reasons people step up to 1000 mg:

• Age 50+. NAD+ decline is steeper between 50 and 70 across multiple tissues (Massudi 2012 measured ~50% drop between age 40 and 60 in human skin; McReynolds 2020 confirmed similar decline curves in plasma and PBMCs). NAMPT expression falls in skeletal muscle and adipose tissue. CD38 expression rises with inflammaging, and CD38 is the dominant NAD+-degrading enzyme. Conversion efficiency from oral NMN to tissue NAD+ drops alongside. The higher dose offsets the lower conversion, not just the lower starting point.
• Metabolic stress. Acute or chronic illness, intense training cycles, recovery from injury, high-stress career periods, jet lag and shift work, and post-surgical recovery all consume more NAD+. PARP activity climbs with DNA damage; sirtuin demand climbs with metabolic load; CD38 expression rises with inflammation. The 1000 mg dose has more headroom for the population that needs it.
• Post-menopausal and andropausal physiology. Estrogen supports NAMPT expression; the post-menopausal drop in estrogen is associated with a measurably steeper NAD+ decline. The Yoshino 2021 Science trial that produced the cleanest insulin-sensitivity signal was specifically run in overweight, prediabetic, post-menopausal women — a population where higher precursor doses are the practitioner default.
• 500 mg didn't move the needle. Some people are simply lower oral responders — pharmacokinetics vary based on SLC12A8 expression, gut microbiome composition affects degradation, CD38 expression varies several-fold between individuals. Stepping to 1000 mg before concluding NMN doesn't work for you is the standard practitioner next step.
• Convenience. One capsule in the morning instead of two, one bottle per month instead of half a bottle, simpler travel kit.

Above 1000 mg, the dose-response data is still maturing. The Liao 2021 dose-finding study tested up to 600 mg/day and saw a clear plateau in walking speed past that point. Higher doses (1200–2000 mg) appear in some practitioner protocols and in the Pencina 2023 PK study (single 1000 mg oral dose tracked across 24 hours), but don't yet have the published RCT outcome support that the 250–1000 mg range does. We position 1000 mg as the high end of the well-evidenced range.

The trial bench — what the 250–1000 mg human RCT data actually shows

• Yoshino 2021 (Science) — 250 mg/day, 10 weeks, 25 overweight prediabetic post-menopausal women. Primary endpoint was muscle insulin sensitivity (hyperinsulinemic-euglycemic clamp). NMN group showed a 25% improvement in muscle insulin sensitivity and upregulation of muscle insulin-signaling and remodeling genes. Plasma NAD+ metabolite changes were measured but the headline was the functional metabolic signal.
• Yamaguchi 2022 — 250 mg/day, 12 weeks, older adult men. Walking speed and grip strength both improved measurably vs placebo. Sleep quality (PSQI score) improved. NAD+ blood metabolites rose.
• Liao 2021 — 300/600/900 mg/day dose-finding RCT, 60 days, older adults. Six-minute walk distance improved dose-dependently up to 600 mg, then plateaued. No safety signals across the dose range. Blood NAD+ rose at all three doses.
• Igarashi 2022 (npj Aging) — 250 mg/day, 12 weeks, older adults. Whole-blood NAD+ rose ~50% from baseline. Gait speed improved measurably; the effect was strongest in the lower-baseline-NAD+ subgroup, consistent with the dose-scaling logic above.
• Yi 2023 — 300/600/900 mg, 60 days, healthy middle-aged adults. Replicated walking-speed and biological-age (TruDiagnostic methylation clock) improvements; the 600 and 900 mg groups outperformed 300 mg on the secondary biological-age endpoint.
• Pencina 2023 — single-dose PK in healthy adults. Confirmed dose-proportional rise in plasma NAD+ metabolites with oral NMN up to 1000 mg, supporting the pharmacokinetic logic of the 1000 mg dose.

The pattern across this bench: the 250–600 mg window covers most of the published primary-endpoint effects, the 600–1000 mg window covers older and more depleted populations and the slower-responder subgroups, and the safety database extends cleanly through 1000 mg/day for at least 8–12 weeks.

What's in it

• β-NMN 1000 mg per capsule, 99%+ purity, HPLC-verified per batch, third-party tested for heavy metals (lead, arsenic, cadmium, mercury), microbial contamination, and identity confirmation
• Vegetable cellulose (HPMC) capsule shell — vegan, no gelatin
• No magnesium stearate, no silicon dioxide, no titanium dioxide, no rice flour bulking, no artificial colors, no proprietary blend, no synthetic excipients
• 60 capsules per bottle — 30-day supply at the standard 1 capsule/day dose, 60-day supply if running 1 capsule every other day during a maintenance phase or alternating with a 500 mg daily dose
• UV-protective HDPE bottle to limit photodegradation; refrigeration not required for unopened or in-use bottles, but cool-and-dry storage extends shelf life
• cGMP-certified manufacturing facility; per-batch certificate of analysis available on request via support@truehealthprotocol.health

Daily protocol

• Default: 1 capsule (1000 mg) in the morning with breakfast, daily, not cycled. Plasma NAD+ rises within hours; tissue NAD+ rises gradually over 2–4 weeks of consistent intake. Consistency beats dose escalation.
• Time-restricted eating window: take with the first meal that breaks your fast, not before. NMN has minor insulinotropic activity in some users; pairing with food smooths the response and supports the SLC12A8 transporter that handles intestinal uptake.
• Evening dose pattern: not recommended. NAD+ has a circadian peak in the morning and trough in late evening; evening NMN can blunt the natural decline that allows for nighttime mitochondrial repair, autophagy, and circadian sirtuin activity (SIRT1's role in BMAL1 deacetylation).
• Maintenance phase: after 6+ months of daily 1000 mg, some users drop to 1000 mg every other day or alternate with 500 mg. This is preference, not a clinical recommendation — daily 1000 mg is also fine indefinitely based on the available safety data.
• If transitioning from 500 mg: step straight to 1000 mg, no titration needed. NMN doesn't have the GI tolerance issue that berberine, magnesium citrate, or high-dose NAC can have at the upper end.
• If you miss a dose: resume the next day at 1000 mg. Don't double up. Tissue NAD+ has enough buffer that a single missed day is invisible at this point.
• Travel: the bottle ships sealed; transfer the day's dose to a small pillbox if you're not bringing the whole bottle. NMN is reasonably temperature-stable for short transit; avoid leaving the bottle in a hot car for prolonged periods.

Stacking — what NMN works harder with

NMN is a precursor. It raises the pool. The molecules that use the pool are where the longevity benefits show up:

• TMG (Trimethylglycine) — methylation buffer. NMN → NAD+ → consumption by sirtuins/PARP → nicotinamide → methylation by NNMT (consumes a methyl group from SAMe) → 1-methylnicotinamide → excretion. At sustained 1000 mg/day NMN intake, methyl-donor demand rises measurably. TMG donates methyl groups directly via the BHMT pathway. Practitioner stacks running 1000 mg+ NMN typically pair 500–1000 mg TMG. TMG 1000 mg.
• Resveratrol — sirtuin activation. SIRT1 is NAD+-dependent and resveratrol-activated (Howitz 2003 Nature, Lagouge 2006 Cell, Baur 2006 Nature). The pairing is the classic Sinclair-lab combo — NMN raises the substrate, resveratrol pulls it through the enzyme. Resveratrol 600 mg.
• Pterostilbene — methylated resveratrol analog. Higher oral bioavailability than resveratrol (Walle 2004 Drug Metab Dispos ~5% vs Kapetanovic 2011 ~80% for pterostilbene), longer half-life, and the same SIRT1 activation profile. Many users running NMN 1000 mg pair pterostilbene rather than resveratrol on PK grounds. Pterostilbene 100 mg.
• Liposomal NAD+ — finished coenzyme delivery. NMN gives you the precursor; liposomal NAD+ delivers the finished molecule via phospholipid encapsulation that bypasses the gastric breakdown that limits direct oral NAD+. Some users stack NMN AM + Liposomal NAD+ early afternoon to bridge the natural circadian dip. Liposomal NAD+ Ultimate 1000 mg.
• Apigenin — CD38 inhibition. CD38 is the primary NAD+-degrading enzyme and its expression rises with age and inflammaging (Camacho-Pereira 2016 Cell Metabolism). Apigenin (50 mg from chamomile/parsley extract) inhibits CD38 in vitro and slows the leak rate, which means more of the NMN you take ends up as tissue NAD+ rather than getting cleaved back to nicotinamide. Apigenin 50 mg + BioPerine.
• CoQ10 + PQQ — mitochondrial complement. NAD+ feeds Complex I; CoQ10 carries electrons from Complex I/II to Complex III; PQQ supports mitochondrial biogenesis via PGC-1α. The trio addresses the mitochondrial axis from substrate to electron carrier to capacity. CoQ10 400 mg · PQQ 20 mg.
• Urolithin A — mitophagy. NMN raises substrate; UroA clears the dysfunctional mitochondria via PINK1/Parkin-driven mitophagy (Andreux 2019 Nature Metabolism, Liu 2022 JAMA Network Open, Singh 2022 Cell Reports Medicine). The renewal loop is feed → use → clear → biogenesis. Urolithin A 500 mg.
• Berberine — AMPK side of the longevity map. The four-pathway longevity stack is sirtuins (NMN/Resveratrol) + AMPK (Berberine/metformin) + autophagy (Spermidine) + senolytics (Fisetin/Quercetin). NMN handles the sirtuin leg. Berberine 500 mg.
• Spermidine — autophagy. NMN supports cellular fuel and signaling; spermidine triggers the cellular cleanup process (autophagy) that recycles damaged proteins and organelles. The two operate on different but reinforcing axes of the longevity map. Spermidine 10 mg.
• Foundational layer — magnesium glycinate, omega-3, vitamin D3+K2. These aren't longevity-specific, but mitochondrial function depends on them as cofactors. If your foundational layer is weak, the precursor stack underperforms. Magnesium Glycinate 400 mg · Omega-3 Fish Oil 2000 mg · Vitamin D3 + K2.

What this product is — and what it is NOT

This is: a high-dose, single-ingredient β-NMN capsule positioned for the older-adult and metabolically-stressed end of the longevity-supplement market, where the published RCT support sits at 600–1000 mg/day rather than the 250 mg headline doses.

This is not:

• Not a stimulant. NMN is not caffeine. The "morning energy" some users report is downstream of better mitochondrial ATP output, not a sympathomimetic effect. Don't expect the kick of a pre-workout.
• Not a treatment for any disease. NMN is a dietary supplement. The Yoshino 2021 insulin-sensitivity signal is research-grade evidence in a specific population, not a clinical claim for diabetes management.
• Not a one-month thing. Tissue NAD+ rises over weeks and the longevity-relevant downstream effects (sirtuin activity, mitochondrial biogenesis, DNA repair throughput) compound over months. Single-bottle results are usually subjective; multi-month results are where the published outcomes sit.
• Not a substitute for sleep, training, or protein. NMN amplifies the foundational work; it doesn't replace it. A 1000 mg NMN dose into a 5-hour-sleep, sedentary, undernourished baseline produces less than a 500 mg dose into a well-managed baseline.
• Not the right starting point if you've never taken NMN before. Start with Pure NMN 500 mg for 6–8 weeks, then step up to 1000 mg if the response was minimal. There's no risk to starting at 1000 mg, but the cost-per-effect math favors the lower dose for younger or less depleted physiologies.

Who this is for, who this is not for

Strong fit: adults 50+, post-menopausal women navigating the steeper NAD+ decline, andropausal men, athletes and high-training-volume populations, recovery-from-illness or post-surgical phases, anyone who tried 500 mg for 6–8 weeks and didn't notice the morning-energy or afternoon-clarity shift most users describe in weeks 2–4, anyone running the Cellular Longevity protocol who wants the higher-dose precursor floor, shift workers and frequent international travelers whose circadian rhythm is chronically perturbed, anyone with an elevated chronic-inflammation baseline (high CRP, autoimmune background, post-infectious recovery).

Not a fit / talk to your physician first: active or recent cancer history (NAD+ supports both healthy and malignant cells; the precautionary practitioner default is to avoid precursor supplementation during active treatment and for the first 12 months after remission, until oncology clears), pregnancy and lactation (no human safety data), under 30 with no specific NAD+-related indication (the decline curve isn't steep enough yet to justify the cost — start with foundations), anyone on chemotherapeutic protocols where NAD+ status is part of the treatment design, anyone with rare PARP-related genetic conditions (talk to a clinical geneticist first).

What to expect on the timeline

• Days 1–14: usually nothing dramatic. Plasma NAD+ rises within hours of the first dose; tissue NAD+ accumulates over weeks; the metabolic effects compound below the level of subjective awareness for most users in this window. A minority report cleaner mornings inside the first week — usually the more depleted or higher-stress baselines.
• Weeks 2–4: easier mornings, steadier afternoon energy, fewer post-lunch crashes — the most commonly reported subjective shifts and consistent with the Yamaguchi 2022 grip-strength + walking-speed timeline. Sleep onset and sleep quality (PSQI subjective measure) often improve in parallel; this is downstream of better daytime mitochondrial function, not a sedating effect.
• Weeks 4–8: baseline cellular energy, exercise recovery, and mental clarity build noticeably. Skin appearance improves in some users (sirtuin activity in the dermal layer, mitochondrial function in keratinocytes). Hair appearance changes lag further.
• Weeks 8–12: the window where the published RCT primary endpoints land — improved insulin sensitivity (Yoshino 2021 at 10 weeks), preserved walking speed in older adults (Yamaguchi 2022 at 12 weeks, Igarashi 2022 at 12 weeks), endothelial function gains (de Picciotto 2016 in NR but mechanism shared).
• Months 3+: the compound-interest phase. Sustained sirtuin activation, ongoing mitochondrial biogenesis, accumulating DNA-repair throughput, and the long-tail effects on biological age (Yi 2023 methylation-clock signal at 60 days, longer cohorts ongoing). This is the window the longevity literature is built on; the first 8 weeks are mostly the loading curve.

Common mistakes to avoid

• Cycling. NMN is not a stimulant or hormone-modulator. There's no published rationale for 5-on/2-off or month-on/month-off cycling. Daily intake is the trial design, daily intake is the practitioner default.
• Empty-stomach evening dosing. Maximizes the wrong things — bypasses food-coupled SLC12A8 uptake support, blunts the natural circadian NAD+ trough that nighttime repair processes depend on. Morning + with breakfast is the trial-replicated pattern.
• Skipping the methyl-donor buffer. Sustained 1000 mg/day NMN with no dietary methyl support can produce subtle methyl-depletion symptoms (low-grade fatigue, irritability) in MTHFR variants and restricted-diet users. The TMG add-on is cheap insurance.
• Stacking too many NAD+ products simultaneously. The catalog has NMN 500, NMN 1000, NR capsules, Liquid NAD+ stick packs, Liposomal NAD+ Ultimate, NAD+ Daily Boost, NAD+ 5-in-1, NAD+ 1000 Pure Focus. Pick one or two complementary products (e.g., NMN AM + Liposomal NAD+ early afternoon) — running four NAD+ products at once is wasted spend.
• Expecting a kick. NMN is a substrate-level intervention; the effects compound over weeks. Users expecting day-1 caffeine-like perception usually conclude the product doesn't work and quit before week 4 — which is roughly when the Yamaguchi/Igarashi gait-speed signal becomes detectable.
• Quitting at week 4. The RCT primary endpoints land at 10–12 weeks. If you're going to evaluate whether NMN is working for you, run at least one full bottle through and ideally two.

FAQ

1000 mg NMN — is that too much? The Liao 2021 dose-finding RCT tested 300, 600, and 900 mg/day for 60 days in older adults and reported no safety signals across the range. The Pencina 2023 single-dose PK study extended to 1000 mg. The published dose-finding work doesn't yet extend cleanly past 1200 mg, which is why we cap our line at 1000 mg as the high end of the well-evidenced range. Practitioner protocols running higher exist, but the published RCT support beyond ~1000 mg is still maturing.

NMN vs NR — which actually works? NR (nicotinamide riboside) was the first oral NAD+ precursor with major clinical trial support (Trammell 2016 Nature Communications, Martens 2018 Nature Communications). NMN is one enzymatic step closer to NAD+ and has built up its own RCT base since 2020 (Yoshino, Yamaguchi, Liao, Igarashi, Yi). Head-to-head RCTs comparing NMN and NR at matched doses are still rare; both raise blood NAD+ in trials. The practical difference: NMN's dose-response curve appears slightly steeper at the older-adult end, NR's safety database is longer (12+ years post-Chromadex commercial availability vs ~5–6 years for oral NMN). Either is a reasonable choice; the catalog stocks both — see Nicotinamide Riboside (NR) capsules.

Do I need TMG with 1000 mg NMN? Methylation demand rises with sustained high-dose NMN intake because nicotinamide is methylated and excreted via NNMT, which pulls methyl groups from SAMe. For most users on 1000 mg/day, dietary methyl donors (eggs, leafy greens, beets, beef liver) are sufficient. For users on restricted diets, MTHFR variants, or running NMN + methylated B vitamins simultaneously, adding 500–1000 mg TMG is the standard practitioner adjustment. It's a buffer, not a requirement — symptoms of low-grade methyl-donor depletion are subtle (fatigue, irritability, mild anxiety) and respond quickly to TMG if they appear.

Should I worry about NMN and cancer? The precautionary position is to avoid NAD+ precursor supplementation during active cancer treatment and for the first 12 months post-remission, then re-evaluate with the oncology team. The reasoning: NAD+ supports DNA repair and metabolic function in all cells, including malignant ones, and some chemotherapeutic protocols intentionally target the NAD+ pathway (CD38-targeting daratumumab, NAMPT inhibitors in certain hematological malignancies). The data here is mixed and rapidly evolving — there are arguments both for and against precursor supplementation in oncology contexts. Default to caution and physician oversight.

Why morning, not evening? NAD+ has a circadian rhythm — peak in the morning, trough late evening. The trough is when nighttime mitochondrial repair, autophagy, and circadian sirtuin activity (SIRT1's role in BMAL1 regulation, the clock-gene feedback loop) happen. Adding NMN evening can blunt the natural trough. Morning dosing rides the circadian peak and aligns with the metabolic demand of the active day. Yamaguchi 2022 specifically noted improved subjective sleep quality with morning NMN dosing — the mechanism is downstream of better daytime mitochondrial function, not a sedative effect.

Can I take NMN with metformin? Yes. NMN raises the NAD+ pool and feeds the sirtuin leg of the longevity map; metformin works primarily through the AMPK leg. The two address different and complementary nodes. There's no published interaction concern. Many longevity protocols run both. (This is general information, not medical advice — talk to your prescriber.)

Can I take NMN with statins, blood thinners, or blood pressure medications? No published interactions with statins or common antihypertensives. NMN has minor effects on platelet function in vitro at high concentrations; if you're on warfarin, apixaban, or another anticoagulant, mention NMN to your prescriber and check INR if applicable. The clinical signal is small; the precaution is standard supplement-medication overlap practice.

Time to first noticeable effect — honestly? Most users report something in weeks 2–4 (cleaner mornings, fewer afternoon energy crashes, easier exercise recovery). A meaningful minority report nothing dramatic for the first 6–8 weeks and then an inflection. About 10–15% report no noticeable subjective shift even at 1000 mg over 8+ weeks — these are the lower oral responders, and at that point the question is whether you're chasing a measurable outcome (NAD+ blood test, improved fasting glucose, grip strength, biological-age clock) or a subjective one. The measurable outcomes show up more reliably than the subjective ones.

Can I open the capsule and mix it into a drink? Yes, but two caveats: NMN is mildly hygroscopic and acid-sensitive, so mix it cold (water, smoothie, kefir) and consume immediately rather than letting it sit. Hot coffee or hot tea will accelerate degradation. The capsule shell is HPMC and dissolves cleanly anyway, so most users don't bother opening it.

Does NMN need to be refrigerated? The unopened bottle is stable at room temperature in the UV-protective HDPE container; cool-and-dry storage extends shelf life. Some longevity influencers refrigerate; it's not required for stability inside the labeled shelf life. Don't freeze (no benefit, condensation risk on the capsule shell when warming back up).

Is there an Amazon version that's cheaper? The β-NMN supply chain has substantial purity and isomer-mix variation. α-NMN is biologically inactive; some lower-cost listings run undeclared mixed-isomer material, lower purity (~95% or below), no third-party COA, or rice-flour bulking inside the capsule. Per-mg-of-true-active cost is often higher on the cheap-looking listings once you account for actual β-NMN content. Our pricing is built around 99%+ HPLC-verified β-NMN with per-batch COA available — the math works out competitive once like-for-like.

I'm under 40 — do I need this? Probably not the 1000 mg dose. The decline curve below 40 is shallow enough that 500 mg or even foundational stack work (sleep, training, methylation support, omega-3 status) covers most of the actionable surface. Pure NMN 500 mg is the under-50 default. Step up if and when the lower dose stops feeling like enough.

Quality and sourcing

β-NMN, 99%+ purity, HPLC-verified per batch. The β-isomer matters — α-NMN is biologically inactive; some lower-cost NMN supplements run mixed-isomer or undeclared-isomer material, which is one of the more common ways the per-mg-of-true-active cost balloons on cheap-looking listings. Third-party tested for heavy metals (lead, arsenic, cadmium, mercury), microbial contamination (total plate count, yeast/mold, E. coli, Salmonella), and identity confirmation. COA available on request via support@truehealthprotocol.health. Manufactured in a cGMP-certified US facility. UV-protective HDPE bottle to limit photodegradation. Vegan HPMC capsule shell — no gelatin, no titanium dioxide, no artificial colors.

Read more

• NMN vs NAD+ — which should you take in 2026
• Best time to take NMN
• NMN side effects — what the research shows
• NMN vs NR — comparison
• Longevity supplements after 40
• Cellular Longevity Protocol
• NAD+ Precursor collection

This product is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. Consult your physician before starting any supplement, especially if you take prescription medication, are pregnant or nursing, have an active or recent cancer history, or have a medical condition. References cited (Yoshino 2021 Science, Yamaguchi 2022, Liao 2021, Igarashi 2022 npj Aging, Yi 2023, Pencina 2023, Trammell 2016 Nature Communications, Martens 2018, Massudi 2012 PLoS ONE, McReynolds 2020 Cell Metabolism, López-Otín 2013/2023 Cell, Howitz 2003 Nature, Lagouge 2006 Cell, Baur 2006 Nature, de Picciotto 2016, Camacho-Pereira 2016 Cell Metabolism, Grozio 2019 Nature Metabolism, Walle 2004 Drug Metab Dispos, Kapetanovic 2011, Andreux 2019 Nature Metabolism, Liu 2022 JAMA Network Open, Singh 2022 Cell Reports Medicine) are for educational context, not implied product claims.